| Adverse reactions during short-term therapy are usually non-serious. Those effects which have been noted include: paraesthesia, particularly a "tingling" feeling in the extremities; some loss of appetite; taste disturbance, polyuria, flushing, thirst, headache, dizziness, fatigue, irritability, excitement, ataxia, depression, reduced libido and occasional instances of drowsiness and confusion. Rarely, photosensitivity has been reported. During long-term therapy, metabolic acidosis and electrolyte imbalance, including hypokalaemia and hyponatraemia may occasionally occur. Hypokalaemia is generally transient and is rarely clinically significant. Osteomalacia with long-term phenytoin therapy, hyperglycaemia and hypoglycaemia, may occasionally occur during long term therapy. The acidosis can usually be corrected by the administration of bicarbonate.Transient myopia has been reported. This condition invariably subsides upon diminution or discontinuation of the medication.Gastro-intestinal disturbances such as nausea, vomiting and diarrhoea.DIAMOX is a sulphide derivative and therefore some side-effects similar to those caused by sulphonamides have occasionally been reported. These include fever, agranulocytosis, thrombocytopenia, thrombocytic purpura, leukopenia, and aplastic anaemia, bone marrow depression, pancytopenia, rash (including erythema multiforme, Stevens-Johnson Syndrome, toxic epidermal necrolysis), anaphylaxis, crystalluria, calculus formation, renal and ureteral colic, and renal lesions. Rarely, fulminant hepatic necrosis has been reported.Other occasional adverse reactions include: urticaria, melaena, haematuria, glycosuria, impaired hearing and tinnitus, abnormal liver function, renal failure and rarely; hepatitis or cholestatic jaundice, flaccid paralysis, and convulsions.Long – term therapy with acetazolamide increases the risk of nephrolithiasis. | |
